Alumis Inc banner

Alumis Inc
NASDAQ:ALMS

Watchlist Manager
Alumis Inc Logo
Alumis Inc
NASDAQ:ALMS
Watchlist
Price: 23.05 USD 0.48% Market Closed
Market Cap: $2.9B

Multiples-Based Value

The Multiples-Based Value for Alumis Inc (ALMS) under the Base Case is 4.15 USD. Compared with the current market price of 23.05 USD, the stock appears Overvalued by 82%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALMS Multiples-Based Value
Base Case
4.15 USD
Overvaluation 82%
Multiples-Based Value
Price $23.05
Worst Case
Base Case
Best Case

Multiples Across Competitors

ALMS Competitors Multiples
Alumis Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Alumis Inc
NASDAQ:ALMS
2.9B USD 119.5 -11.8 -5.7 -5.7
US
Eli Lilly and Co
NYSE:LLY
887.6B USD 13.6 43 29 31
US
Johnson & Johnson
NYSE:JNJ
574.2B USD 6.1 21.4 14.9 18.3
UK
AstraZeneca PLC
LSE:AZN
236.2B GBP 5.3 30.3 16.7 23.6
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.5 11.6 13
US
Merck & Co Inc
NYSE:MRK
300.5B USD 4.6 16.5 10.2 12.4
CH
Novartis AG
SIX:NOVN
233.6B CHF 5.2 20.9 12.9 16.6
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6 386.8 970
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.3 7.6 8.9
US
Pfizer Inc
NYSE:PFE
153.1B USD 2.4 19.7 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
118B USD 2.5 16.7 7.1 8.7
P/E Multiple
Earnings Growth PEG
US
Alumis Inc
NASDAQ:ALMS
Average P/E: 22
Negative Multiple: -11.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
43
31%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.4
8%
2.7
UK
AstraZeneca PLC
LSE:AZN
30.3
25%
1.2
CH
Roche Holding AG
SIX:ROG
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.5
14%
1.2
CH
Novartis AG
SIX:NOVN
20.9
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.7
16%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Alumis Inc
NASDAQ:ALMS
Average EV/EBITDA: 50.4
Negative Multiple: -5.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29
21%
1.4
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.4
UK
AstraZeneca PLC
LSE:AZN
16.7
12%
1.4
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10.2
4%
2.5
CH
Novartis AG
SIX:NOVN
12.9
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
2%
3.8
US
Pfizer Inc
NYSE:PFE
7.6
-8%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Alumis Inc
NASDAQ:ALMS
Average EV/EBIT: 111.3
Negative Multiple: -5.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.3
6%
3
UK
AstraZeneca PLC
LSE:AZN
23.6
21%
1.1
CH
Roche Holding AG
SIX:ROG
13
6%
2.2
US
Merck & Co Inc
NYSE:MRK
12.4
6%
2.1
CH
Novartis AG
SIX:NOVN
16.6
9%
1.8
IE
E
Endo International PLC
LSE:0Y5F
970
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
2%
4.5
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.7
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett